Senior CRA: Remote Clinical Trial Site Lead

Parexel; Topeka (KS); On-site; USD 90,000 - 120,000; Full time

Job summary

Parexel FSP is seeking Sr Clinical Research Associates to join our team in the United States. The Senior CRA will manage investigator sites, monitor trials, and oversee close-out activities to ensure patient safety and data quality in compliance with GCP and applicable laws.

The Sr CRA will work with the Site Care Partner and study team across activation, monitoring, and close-out, ensuring timely delivery of study milestones and robust site engagement. Significant travel (60–80%) is expected.

Qualifications

• Extensive knowledge of clinical trial methodologies, ICH/GCP, FDA regulations and local country requirements.
• Monitoring experience: minimum 3 years in clinical research site monitoring ( Oncology preferred).
• Global clinical trial experience beneficial.
• Must be fluent in English and the local language(s) where work occurs.

Responsibilities

• Oversee monitoring responsibilities and study conduct to ensure patient safety and quality.
• Manage site activation through to database lock, ensuring timelines and quality deliverables.
• Act as primary point of contact for investigator sites and coordinate with SCP and study team.
• Provide training and guidance to site staff on protocol requirements and study procedures.
• Support enrollment and recruitment activities at the site level in partnership with the SCP.

Skills

Clinical trial knowledge

Monitoring experience

Oncology experience

Global trials

English fluency

Travel willingness

Driver's license

Passport

Job description

Parexel FSP is seeking Sr Clinical Research Associates to join our team in the United States. The Senior CRA will manage investigator sites, monitor trials, and oversee close-out activities to ensure patient safety and data quality in compliance with GCP and applicable laws.

The Sr CRA will work with the Site Care Partner and study team across activation, monitoring, and close-out, ensuring timely delivery of study milestones and robust site engagement. Significant travel (60–80%) is expected.